Jennifer Lee - Feb 1, 2023 Form 4 Insider Report for RHYTHM PHARMACEUTICALS, INC. (RYTM)

Role
EVP, Head of North America
Signature
/s/ Hunter Smith, Attorney-in-Fact for Jennifer Chien
Stock symbol
RYTM
Transactions as of
Feb 1, 2023
Transactions value $
$0
Form type
4
Date filed
2/3/2023, 03:06 PM
Previous filing
Feb 15, 2022
Next filing
Feb 14, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RYTM Restricted Stock Units Award $0 +18.1K $0.00 18.1K Feb 1, 2023 Common Stock 18.1K Direct F1, F2
transaction RYTM Stock Option (Right to Buy) Award $0 +46.9K $0.00 46.9K Feb 1, 2023 Common Stock 46.9K $27.35 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.
F2 The restricted stock units vest as to 25% of the total shares on each of February 1, 2024, February 1, 2025, February 1, 2026 and February 1, 2027. The restricted stock units have no expiration date.
F3 The stock options were granted on February 1, 2023. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date.